LakeShore Biopharma Co., Ltd (LSB) Research

LakeShore Biopharma Co., Ltd is a biopharmaceutical firm focused on the discovery, advancement, manufacturing, and marketing of vaccines and therapeutic biologics. Its primary targets are infectious diseases and various forms of cancer. At the core of its innovation is a proprietary PIKA immunomodulating technology platform, which underpins its product pipeline, featuring a PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. The company maintains an international presence, conducting operations across China, the United States, Singapore, the United Arab Emirates, and the Philippines. Originally founded in 2002 and based in Beijing, China, the entity was known as YS Biopharma Co., Ltd until it officially changed its name to LakeShore Biopharma Co., Ltd in May 2024.

Market snapshot

Symbol
LSB
Price
$0.63
Day change
0.00%
Market cap
$18.7M
P/E ratio
-0.48x
52-week range
0.574-8.6
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Allakos Inc. (ALLK)
  • AnPac Bio-Medical Science Co., Ltd. (ANPC)
  • Elevation Oncology, Inc. (ELEV)
  • Freeline Therapeutics Holdings plc (FRLN)
  • Gemini Therapeutics, Inc. (GMTX)
  • Invacare Corporation (IVC)
  • Liminal BioSciences Inc. (LMNL)
  • MEI Pharma, Inc. (MEIP)

Recent insider activity

  • Shao Hui David — trade (0 shares) on 2026-03-18
  • Shao Hui David — trade (0 shares) on 2026-03-18
  • Wang Xu — trade (203464 shares) on 2026-03-18
  • Xue Linnan — trade (0 shares) on 2026-03-18
  • Yu Rui — trade (203464 shares) on 2026-03-18

Open LakeShore Biopharma Co., Ltd (LSB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.